Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT05016219 Recruiting - Clinical trials for Mild Cognitive Impairment

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

Start date: August 22, 2023
Phase: N/A
Study type: Interventional

Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light [RL]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that will stimulate the circadian system and provides a 40 Hz flicker (RL); or (4) a light source that will stimulate the circadian system and provides a random flicker (placebo condition for rhythmic light). Following a baseline week, participants will experience his/her assigned lighting condition for two hours in the morning for 8 weeks. After a 4-week washout period, a final round of assessments will be obtained. Study assessments (except for the Pittsburgh Sleep Quality Index and Montreal Cognitive Assessment) will be collected at the end of each week, for a total of 8 assessments.

NCT ID: NCT05010603 Recruiting - Alzheimer Disease Clinical Trials

Late Onset Alzheimer's Disease

LOAD
Start date: November 15, 2016
Phase:
Study type: Observational

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

NCT ID: NCT05009524 Recruiting - Alzheimer Disease Clinical Trials

The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI)

iPACES
Start date: August 23, 2021
Phase: N/A
Study type: Interventional

The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for persons with mild cognitive impairment (MCI). Participants will include persons with MCI and their co-residing partner who both exercise at home 3-5 times per week for at least 6 months and are followed through one year. All participation is "remote" (completed at home), with all equipment (pedaler, tablet, etc.) supplied directly to the home, and with all study measures completed via videoconference and mail.

NCT ID: NCT05007353 Recruiting - Alzheimer Disease Clinical Trials

The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study

SINGER
Start date: August 23, 2021
Phase: N/A
Study type: Interventional

A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. The SINGER study is a 2-year randomized controlled trial that aims to test the efficacy and safety of these lifestyle changes, including diet and cardiovascular risk factor management, cognitive and physical exercises, in delaying cognitive decline in older adults at risk of dementia.

NCT ID: NCT05004987 Recruiting - Clinical trials for Major Depressive Disorder

Aβ Dynamics in LLMD

Start date: February 4, 2022
Phase: Phase 4
Study type: Interventional

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).

NCT ID: NCT05003830 Recruiting - Alzheimer Disease Clinical Trials

Application of Multi-probe PET/MR Imaging in the Diagnosis and Evaluation of Alzheimer's Disease

Start date: July 1, 2020
Phase:
Study type: Observational

Alzheimer's disease (AD) is the most common cause of cognitive impairment, and its diagnosis requires a comprehensive analysis of the results of medical history, neuropsychological evaluation, imaging and laboratory tests. Among them, it has been widely recognized that amyloid PET imaging is used in the early diagnosis of AD, tau protein PET imaging is used in the assessment of the progression of AD, and the glucose metabolism PET imaging is used in the assessment of nerve damage. MRI can provide structure, blood perfusion, neural network connection damage and other information through multi-sequence scans. With the help of the PET/MR multi-modal imaging platform and multi-probe imaging technology, it can provide more sensitive and accurate imaging information for early diagnosis and disease assessment of AD, and provide a basis for clinical treatment decision-making.

NCT ID: NCT04994847 Recruiting - Alzheimer Disease Clinical Trials

APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease

Start date: May 1, 2021
Phase:
Study type: Observational

The purpose of this study is to track changes in the brain related to Alzheimer's disease. The results from this study will be used to develop new approaches to prevent or delay the onset of memory and thinking problems associated with Alzheimer's.

NCT ID: NCT04992975 Recruiting - Clinical trials for Mild Cognitive Impairment

Brain Iron Toxicity and Neurodegeneration - A 7T MRI Study

BITaN
Start date: September 10, 2021
Phase:
Study type: Observational

A longitudinal observational neuroimaging study of individuals with Early Onset Alzheimer's disease during the prodromal phase, and matched control group - Ultrahigh Field MRI study at 7T

NCT ID: NCT04992195 Recruiting - Stroke Clinical Trials

Impact of COVID-19 Vaccines on Cerebrovascular Health

Start date: July 5, 2021
Phase:
Study type: Observational

Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future. On the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise "young-and-fit" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health. In this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.

NCT ID: NCT04973709 Recruiting - Delirium in Old Age Clinical Trials

Prevalence of Dementia and Delirium in Outpatient Clinics (DESTAN Trial)

Start date: August 5, 2021
Phase:
Study type: Observational

The aim of this study is to assess the prevalence and etiologic risk factors of delirium in outpatient geriatric patients and also hospitalized patients.